United States: With Its Vanda Pharma And Berkheimer Memos, USPTO Provides Increased Clarity And Predictability In The Patent Eligibility Determination In A Further Boost For Stakeholders And Innovators In Personalized Medicine

Last Updated: July 25 2018
Article by Muriel M Liberto

In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed. Cir. 2018), we have had more good news for the patent eligibility of claims relating to diagnostic or similar tests utilized in treating patients. If you’re not familiar with the Vanda Pharma decision, and want more detail, see my April post on the firm’s Global IP Matters blog HERE.

Briefly, in Vanda Pharma the claims related to a method of treating schizophrenia patients with a drug (iloperidone) in which the steps of the method included genotyping the patient and adjusting the dose of the drug based upon the patient’s genotype. Two judges of the three-judge panel in Vanda Pharma found these claims patent eligible under the first step of the Mayo/Alice inquiry, which asks whether the claims as a whole “are directed to” excluded subject matter. Importantly, where the answer to this question is “no,” the inquiry ends and the claims are deemed eligible. There is no need to proceed to the second step, which asks whether the elements of the claims “in addition to” the alleged judicial exceptions (e.g., laws of nature, natural products, abstract ideas) amount to “significantly more” than an attempt to claim the exceptions themselves.

In finding that these claims were, as a whole, not directed to excluded subject matter, the majority characterized the claims as “a new way of using an existing drug that is safer.” The evidence below showed that performing the claimed method reduces the risk of a serious side effect of the drug, referred to as QTc prolongation, by identifying patients at increased risk based on genotype and adjusting the amount of the drug administered to them, thereby reducing the risk.

Importantly, the majority in Vanda Pharma referenced the well-known dicta in Mayo distinguishing the ineligible claims in that case as “[u]nlike, say, a typical patent on a new drug or a new way of using an existing drug” which “confine their reach to particular applications of those laws.” But as positive as the Vanda Pharma decision was, it came with a caveat. It was the majority decision of a three-judge panel in which the dissenting judge, Chief Judge Prost, would have found “the asserted patent claims to be directed to a law of nature.” Moreover, Judge Prost found “no inventive concept in the claims once the natural law at issue is properly understood in view of Mayo,” and in that view the natural law was “the fact that a reduction of iloperidone dosage in poor metabolizers to the [sic] may reduce QTc prolongation.” From there she also found that “[t]he recitation of specific dosages adds no more than a conventional application of that natural law,” despite her acknowledgement of the evidence below regarding the unpredictability in the art as to whether any dose adjustment was actually needed for poor metabolizers, and if so what that dose would be to achieve “normal” pharmacokinetic profile. Judge Prost’s view was that the difference in specific administering steps between the asserted claims in Vanda Pharma and those in Mayo was “of no moment.” So we were left with the chilling prospect that Prost’s view could still one day become a majority view on the Federal Circuit, absent some action by the US Supreme Court which although hoped for does not seem forthcoming anytime soon.

That hasn’t changed. But in the meantime, the US Patent and Trademark Office (USPTO) has embraced the majority opinion in Vanda Pharma in the form of a memo to the patent examining corps expressly stating that “method of treatment claims that practically apply natural relationships should be considered patent eligible” under the first step of the Mayo inquiry (technically Step 2A). This is even better than the unofficial patent office policy which focused the analysis on the second part of the Mayo inquiry and asked whether the combination of steps not “directed to” judicial exceptions (i.e., the wet lab steps) was routine and conventional in the prior art, and importantly, required examiners to substantiate a finding of “routine and conventional” with evidence, such as prior art publications.

That approach provided some clearer basis for challenging the rejection but the rubric seems to have been unevenly applied within the examining corps, and convincing a particular examiner of even the need to substantiate the rejection with evidence, much less how that evidence should be applied, sometimes required the intervention of a subject matter specialist. All of which increases the time and transaction costs of prosecution. Fortunately, at least the requirement that examiners substantiate a finding of “routine and conventional” with evidence was recently formalized in another memo following the Federal Circuit’s decision in Berkheimer v. HP Inc. 881 F.3d 1360 (Fed. Cir. 2018). In Berkheimer, the court held that the question of whether the elements of a claim “in addition to” those reciting judicial exceptions represent “well-understood, routine, conventional activity” raises a disputed issue of fact. The Berkheimer memo expressly provides that a conclusion of “routine and conventional” can only be reached where the elements are “widely prevalent or in common use in the relevant industry.” The memo goes on to provide explicit guidance regarding the kind of factual evidence that must be found to support this conclusion.

The Vanda Pharma memo goes even further than the Berkheimer memo toward easing the path to patent eligibility by acknowledging that methods of treating are eligible under the first step of the Mayo inquiry. This means that time and related costs addressing eligibility rejections should go way down for these types of claims because an examiner can now find them eligible on their face, without the need to address whether or not there are steps “in addition to” those reciting judicial exceptions that represent “well-understood, routine, conventional activity.” This streamlined approach should lead to the withdrawal of many standing rejections and is likely to reduce the incidents of new rejections of claims linking diagnostic or similar methods with treating patients.

It bears mentioning that these positive developments reflect the remarks given by Director Andrei Iancu to the US Chamber of Commerce’s Patent Policy Conference back in early April. Director Iancu promised that the USPTO would do “everything we can” within its mandate to increase the clarity and predictability of the eligibility requirements, noting that they are “actively looking for ways to simplify the eligibility determination for our examiners through forward-looking guidance” and further promising that “[t]hrough our administration of the patent laws . . . the USPTO can lead, not just react to, every new case the courts issue.” Those remarks were made on April 11, 2018, and already we have seen two very helpful memos in the form of the Berkheimer memo (April 19th) and the Vanda Pharma memo (June 7th). Pending some further action by the Federal Circuit to cloud the presently clearing skies, the future is indeed looking very bright.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions